Heather C. Rice

Assistant Professor

Oklahoma Medical Research Foundation
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

About

Heather C. Rice is an Assistant Professor at the Oklahoma Medical Research Foundation in the United States. Her research focuses on neurobiology, particularly in the context of Alzheimer's disease. Recent work includes modeling presynaptic inhibition related to the amyloid precursor protein, aiming to understand mechanisms that may prevent excessive synaptic modification.

Articles (8)

Neurite outgrowth is essential for neural circuit formation and is tightly regulated by secreted factors and their receptors. The secreted extracellular domain of the amyloid precursor protein (sAPPα) has been shown to modulate neurite outgrowth. Recently, the gamma amino butyric acid receptor type-B subunit 1a (GABA B R1a) was identified as an sAPPα binding partner that mediates its effects on synaptic transmission. Here, we investigated whether this interaction also regulates neurite outgrowth. In mouse primary hippocampal neurons of either sex, the GABA B R agonist baclofen reduced axon length; whereas its antagonist CGP54626 increased axon length in primary hippocampal neurons. Moreover, GABA B R1a knock-out increased axon length and abolished the effect of baclofen. Application of sAPPα reduced axon length, an effect that required the presence of both GABA B R1a and the extension domain of sAPPα, which mediates its binding to GABA B R1a. Similarly, the APP 17mer peptide, which is sufficient to bind GABA B R1a and mimic the effects of sAPP on synaptic transmission, reduced axon outgrowth in wild-type but not in GABA B R1a-deficient neurons. Together, these findings indicate that the 1a isoform contributes to GABA B R-dependent suppression of neurite outgrowth and mediates the inhibitory effect of sAPPα on neurite outgrowth.

Year:

2026

INTRODUCTION Previous simulations of Hebbian associative memory models inspired the malignant synaptic growth hypothesis of Alzheimer's disease (AD), which suggests that cognitive impairments arise due to runaway synaptic modification resulting from poor separation between encoding and retrieval. METHODS We computationally model presynaptic inhibition by the recently identified interaction of soluble amyloid precursor protein alpha (sAPPα) with γ ‐aminobutyric acid type B receptor (GABA B R) as one potential biological mechanism that can enhance separation between encoding and retrieval. RESULTS Simulations predict that the dual effect of sAPPα on long‐term potentiation and presynaptic inhibition of glutamatergic synapses maintains effective associative memory function and prevents runaway synaptic modification. Moreover, computational modeling predicts that sAPPα, which interacts with the 1a isoform of GABA B R, is more effective than the GABA B R agonist baclofen at stabilizing associative memory. DISCUSSION Molecular mechanisms that enhance presynaptic inhibition, such as sAPPα‐GABA B R1a signaling, are potential therapeutic targets for preventing cognitive impairments in AD. Highlights Computational modeling of Hebbian associative memory provides a framework for understanding the functional basis of Alzheimer's disease. Soluble amyloid precursor protein (sAPPα) presynaptic activation of γ‐aminobutyric acid B (GABA B ) receptors prevents runaway synaptic modification in associative memory models. sAPPα is more effective than baclofen at stabilizing associative memory.

Year:

2025

Year:

2025

INTRODUCTION Previous simulations of Hebbian associative memory models inspired the malignant synaptic growth hypothesis of Alzheimer’s disease (AD), which suggests that cognitive impairments arise due to runaway synaptic modification resulting from poor separation between encoding and retrieval. METHODS We computationally model presynaptic inhibition by the recently identified interaction of soluble amyloid precursor protein (sAPPα) with the γ-aminobutyric acid type B receptor (GABA B R) as one potential biological mechanism which can enhance separation between encoding and retrieval. RESULTS Simulations predict that the dual effect of sAPPα on long-term potentiation and presynaptic inhibition of glutamatergic synapses maintains effective associative memory function and prevents runaway synaptic modification. Moreover, computational modeling predicts that sAPPα, which interacts with the 1a isoform of GABA B R, is more effective at stabilizing associative memory than the GABA B R agonist Baclofen. DISCUSSION Molecular mechanisms that enhance presynaptic inhibition, such as sAPPα-GABA B R1a signaling, are potential therapeutic targets for preventing cognitive impairments in AD.

Year:

2025

Amyloid precursor protein (APP) is a type I transmembrane protein that undergoes proteolytic processing to generate amyloid-β, the main component of amyloid plaques found in brains with Alzheimer’s disease. The proteolytic processing of APP also generates soluble APP alpha (sAPPα) which can modulate synaptic transmission and neurite outgrowth through the γ-aminobutyric acid type B receptor (GABA B R). Whether GABA B R mediates functions of sAPPα in other neural cell types such as glia remains unknown. sAPPα binds the R1a subunit isoform of GABA B R1 which contains two sushi domains absent in R1b. It is unclear whether both GABA B R1 isoforms are expressed equally across brain cell types. We determined relative RNA levels of the GABA B R1a and 1b isoforms in oligodendrocytes, microglia, endothelial cells, astrocytes, and neurons in adult mice using two approaches. We developed a GABA B R1 isoform-specific RNAseq analysis workflow to probe a publicly available dataset. We also isolated five cell types from a single mouse brain and performed RT-qPCR. We show that the GABA B R1a and 1b isoforms are differentially expressed among cell types. GABA B R1a expression was highest in oligodendrocytes and GABA B R1b expression was highest in astrocytes, suggesting that sAPPα-mediated GABA B R signaling may be most prominent in oligodendrocytes. We also confirmed that APP is expressed in all five cell types and showed that APP RNA levels are highest in oligodendrocytes. Together, our findings uncover cell type-specific expression of GABA B R isoforms and highlight oligodendrocytes as a principal cell type for GABA B R1a-mediated APP signaling, providing a foundation for future mechanistic studies.

Year:

2025

Neurite outgrowth is essential for neural circuit formation and is tightly regulated by secreted factors and their receptors. The secreted extracellular domain of the amyloid precursor protein (sAPPα) has been shown to modulate neurite outgrowth. Recently, the gamma amino butyric acid receptor type-B subunit 1a (GABA B R1a) was identified as an sAPPα binding partner that mediates its effects on synaptic transmission. Here, we investigated whether this interaction also regulates neurite outgrowth. In primary hippocampal neurons, the GABA B R agonist baclofen reduced axon length; whereas, its antagonist CGP54626 increased axon length in primary hippocampal neurons. Moreover, GABA B R1a knockout increased axon length and abolished the effect of baclofen. Application of sAPPα reduced axon length, an effect that required the presence of both GABA B R1a and the extension domain of sAPPα, which mediates its binding to GABA B R1a. Similarly, the APP 17mer peptide, which is sufficient to bind GABA B R1a and mimic the effects of sAPP on synaptic transmission, reduced axon outgrowth in wildtype but not in GABA B R1a-deficient neurons. Together, these findings indicate that the 1a isoform contributes to GABA B R-dependent suppression of neurite outgrowth and mediates the inhibitory effect of sAPPα on neurite outgrowth. Statement of Significance Amyloid precursor protein (APP) plays a central role in Alzheimer’s disease, yet its normal functions are not fully understood. In this study, we uncover a previously unrecognized role of the GABA B Receptor in mediating the inhibitory effects of sAPPα on neurite outgrowth. These findings provide mechanistic insight into how disruptions in APP signaling could influence both normal brain development and pathological processes in neurodevelopmental disorders and Alzheimer’s disease.

Year:

2025

The isolation of specific cell types of the brain is essential to study cell-type-specific differences in complex neurological diseases such as Alzheimer’s disease. This protocol isolates oligodendrocytes, microglia, endothelial cells, astrocytes, and neurons from a single mouse brain. The process involves gentle tissue homogenization, debris removal, and sequential sorting of five distinct cell types. We validate cell purity and viability using flow cytometry and RT-qPCR. This protocol is well-suited for a range of downstream applications, including genomics, transcriptomics, and proteomics. Abstract Figure

Year:

2025

INTRODUCTION Ventral tegmental area (VTA) dopamine has been implicated in neuropsychiatric symptoms observed in Alzheimer’s disease (AD) patients. Dopaminergic dysfunction and aberrant firing are observed in mouse AD models, but the specific roles of Aβ and tau have not been determined. METHODS We performed electrophysiological recordings of single VTA dopamine neuron firing in the 3xTg-AD model, followed by recordings in amyloid (APP NL-G-F )- and human tau (hTau)-based models to determine the pathological triggers of impaired firing. RESULTS In vivo dopamine neuron recordings showed fewer spikes in defined bursts in 3xTg-AD mice versus controls. Ex vivo studies showed an impaired ability to sustain firing during depolarization, which was mimicked with depolarized current in wild type neurons. Dopamine neurons transduced with hTau reflected firing aberrations and impaired bursting, but the effects were not recapitulated in the APP NL-G-F model, DISCUSSION These results suggest that hTau specifically induces hyperexcitable states within individual dopamine neurons, disrupting burst firing. This dopaminergic dysfunction could compromise reward learning and contribute to the psychiatric symptoms observed in AD.

Year:

2025

Collaborators (3)

Michael Beckstead

Professor

Oklahoma Medical Research Foundation

UNITED STATES
View details

Sarah Ocanas

Assistant Professor

Oklahoma Medical Research Foundation

UNITED STATES
View details

Willard Freeman

Professor

Oklahoma Medical Research Foundation

UNITED STATES
View details